Hospital-acquired infection (HAI) or nosocomial infection can be contracted from the environment or staff of a healthcare facility. It can be spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. The recent global resurgence of HAIs including discovery of new pathogens, recurrence of old infections and rapid spread of antimicrobial resistant pathogens. Diagnosis of such diseases is essential for prompt and efficient treatment of patients thereby reducing the overall duration of hospital stay, cost of healthcare, patient morbidity and mortality rates. HAIs are considered as a significant cause of death and are acquired while receiving healthcare treatment. Rapid adoption of advanced molecular diagnostics methods, well defined regulatory framework and observation guidelines are the major factors driving the North America hospital acquired disease testing market.
The global hospital acquired disease testing market report estimates the market size (Revenue USD million – 2014 to 2021) for market segmentation based on disease test (blood stream associated infection, MRSA infection, Hospital-acquired pneumonia, surgical associated infection, UTI, Gastroenteritis, puerperal fever, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global hospital acquired disease testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital acquired disease testing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global hospital acquired disease testing market and included in this report are Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche, Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc. and others.